FNIP1 Mutations Cut Cardiometabolic Disease Odds 60% in 1-in-7,000 Carriers
Updated
Updated · ScienceAlert · Aug 12
FNIP1 Mutations Cut Cardiometabolic Disease Odds 60% in 1-in-7,000 Carriers
3 articles · Updated · ScienceAlert · Aug 12
Summary
A Nature study of more than 1 million people found 155 carriers of rare protein-truncating FNIP1 mutations, who showed about 60% lower odds of diabetes, heart disease and related metabolic disorders.
FNIP1 normally helps restrain cellular energy use; when partially disabled, that brake appears to lift, shifting the body toward burning rather than storing energy and improving blood sugar, liver fat and blood lipids.
Lab work backed the signal: silencing FNIP1 in human liver cells activated fat-burning genes, while mice on a high-fat, high-fructose diet gained less fat and had better insulin sensitivity and less liver damage.
The mutations also appeared to favor healthier fat distribution, and researchers separately found PDE3B variants with stronger beneficial lipid effects in women than in men.
Regeneron researchers said FNIP1 could become a drug target with GLP-1-like metabolic benefits, but warned that fully disrupting the pathway can cause serious problems and may not safely replicate natural mutations.
Could a rare genetic flaw that forces cells to burn fat hold the key to replacing current weight-loss drugs?
How can scientists safely mimic a rare genetic mutation to cure diabetes without triggering severe systemic side effects?
Unlocking the FNIP1 "Metabolic Brake": 60% Lower Cardiometabolic Risk and the Future of Liver-Targeted RNAi Drugs
Overview
A global study of over one million people identified FNIP1 as a key gene controlling how the body manages energy and fat. Rare individuals with one inactive copy of FNIP1 have healthier fat storage, lower risk of diabetes and heart disease, and more muscle mass, without losing overall weight. This is because FNIP1 normally acts as a 'metabolic brake.' When partially disabled, it boosts fat burning and turns white fat into energy-burning brown fat. To safely mimic this effect, scientists are developing liver-targeted therapies using GalNAc-siRNA, which improve metabolism without the muscle loss seen in current weight-loss drugs.